Fig. 5From: Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysisMeta-analysis estimated PFS comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of estimation of 2-yr PFS; (b) subgroup of estimation of 3-yr PFS. PFS, progression-free survivalBack to article page